Theralink currently supports preclinical and clinical studies across 18 biopharma clients, including multinational corporations...
Theralink’s RPPA (Reverse Phase Protein Array) Technology to be deployed to support and enhance Genomic insights and may ultima...
Denver, Colorado — March 21, 2022 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision med...
Denver, Colorado — March 14, 2022 — Theralink Technologies (OTC: THER) (“Theralink” or the “Company”), a precision onc...
DENVER, February 24, 2022 -- Theralink® Technologies - (OTC: THER) ("Theralink" or the "Company"), announces today that it has...
DENVER, October. 22, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine molecu...
DENVER, March. 29, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine and mol...
DENVER, Feb. 22, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"), In a recent announcement by R...
DENVER, Jan. 27, 2021 -- Theralink® Technologies - (OTC: OBMP) ("Theralink" or the "Company"), a precision medicine molecular...
DENVER, Colorado — January 6, 2021 —Theralink Technologies (OTC: OBMP) (“Theralink” or the “Company”), a molecular pro...